menu
    • menu
    [{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Kings College London","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"STAR0602","moa":"TCR-V beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Marengo Therapeutics \/ King\u2019s College","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ King\u2019s College"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STAR0602","moa":"TCR-V beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Marengo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STAR0602","moa":"TCR-V beta","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Marengo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Marengo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Marengo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"STAR002","moa":"TCR-V beta","graph1":"Oncology","graph2":"Preclinical","graph3":"Marengo Therapeutics","amount2":1.5900000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.5900000000000001,"dosageForm":"","sponsorNew":"Marengo Therapeutics \/ Ipsen","highestDevelopmentStatusID":"4","companyTruncated":"Marengo Therapeutics \/ Ipsen"},{"orgOrder":0,"company":"Marengo Therapeutics","sponsor":"Ipsen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"T Cell Engager","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Marengo Therapeutics","amount2":1.2,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"","sponsorNew":"Marengo Therapeutics \/ Ipsen","highestDevelopmentStatusID":"2","companyTruncated":"Marengo Therapeutics \/ Ipsen"}]

    Find Clinical Drug Pipeline Developments & Deals by Marengo Therapeutics

    Menu

    Marengo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : T Cell Engager

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Ipsen

                            Deal Size : $1,200.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ipsen and Marengo Announce Partnership for Precision T Cell Engagers

                            Details : Research will focus on using Marengo’s TriSTAR platform to reinvigorate and mobilize selective V beta T cells to boost anti-tumor activity in patients with difficult-to-treat cold tumors.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 07, 2024

                            Lead Product(s) : T Cell Engager

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Ipsen

                            Deal Size : $1,200.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STAR0602

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cel...

                            Details : STAR0602, is a fusion protein that binds to a specific region of TCR Vβ and delivers a unique activation signal on the same T cell, leading to a selective expansion of the targeted T cell subclones. STAR0602 is the first T cell activator generated by Ma...

                            Brand Name : STAR0602

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 28, 2022

                            Lead Product(s) : STAR0602

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STAR002

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Ipsen

                            Deal Size : $1,592.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candida...

                            Details : Marengo will lead the preclinical development efforts and will expense related costs until the submission of an Investigational New Drug (IND) application to the U.S. FDA. Ipsen will assume responsibilities for clinical development and commercialization ...

                            Brand Name : STAR002

                            Molecule Type : Large molecule

                            Upfront Cash : $45.0 million

                            August 01, 2022

                            Lead Product(s) : STAR002

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Ipsen

                            Deal Size : $1,592.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STAR0602

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference

                            Details : STAR0602, is an antibody fusion molecule that binds and activates a specific Vβ TCR variant T cell subset while also delivering additional signals to the same T cell to further re-program the T cell to enhance anti-tumor activity.

                            Brand Name : STAR0602

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 06, 2022

                            Lead Product(s) : STAR0602

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Marengo Therapeutics

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : STAR0602

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Kings College London

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Marengo Therapeutics and King’s College London Advance ImmunoOncology Research Collaboration

                            Details : STAR0602, is an antibody fusion molecule that binds and activates a specific Vβ TCR variant T cell subset while also delivering additional signals to the same T cell (known as cis-targeting) to further reprogram the T cell, to enhance anti-tumor activit...

                            Brand Name : STAR0602

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 08, 2021

                            Lead Product(s) : STAR0602

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Kings College London

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth